AB0310 STUDY “AR-CAT INICI”: MANAGEMENT OF EARLY RHEUMATOID ARTHRITIS IN CATALONIA
Authors: C. Perez-Garcia, J. Rovira Aguilar, L. Mateo, J. A. Gómez-Puerta, M. Valls Roc, G. Salvador Alarcon, R. Morlà, S. Holgado Pérez, C. Diaz-Torne, M. Sallés Lizarzaburu, C. García Gomez, S. Castro, N. Montala Palau, H. Borrell Paños, S. Mínguez, M. Lopez Lasanta, V. Ruiz-Esquide, C. Pitarch Grau, N. Busquets-Pérez, H. Corominas, A. Garcia Guillen, S. Rodriguez-Muguruza, M. Martínez-Morillo, R. Sanmartí
Journal: Annals of the Rheumatic Diseases (2022)

Background Given the progressive change in the management of inflammatory diseases,an observational study was conducted on the management of Early Rheumatoid Arthritis (ERA) in Catalonia. Objectives To know the management of ERA in Catalonia, to assess whether the recommendations of the EULAR/ACR guidelines are followed and to study the causes of management variability,to set improvement objectives. Methods An observational,descriptive,and cross-sectional study was conducted,with data collection from June 15 to 30, 2021.The rheumatologists’ partners of the Catalan Society of Rheumatology were the object of study. An online survey was conducted with 304 members on the management of the ERA. Variables related to the characteristics of the respondents,the derivation and variables of the disease including clinical variables,type of treatment and outcomes used for follow-up including the impact of the SARS-CoV2 pandemic were included.The univariate study was performed using a study of proportions with Pearson’s correlation. Results A total of 105 members (34.5%) responded to the survey.11.6%&gt;60 y, only 7.8% &lt;30y. 99% were in public assistance.The number of rheumatologists per service is 7.2[1-17],but 34.2% had&lt; 5 rheumatologists,with a reference population of 200,000-300,000p in 42% of respondents.The number of weekly visits made is 67.5[20-130].42.2% do not have a monographic RA or ERA dispensary and 30.4%not have specialized nursing. Characteristics of ERA :77.5% are derived from primary care(PC),52% have been between 6 weeks,42.1%&gt;3 months.54.9% make a first visit within 2-4 weeks of PC referral and 14.7%&gt; 8 weeks.100%provide previous analysis,only 47% had had RX performed.98% were previously treated(50.4%NSAIDs + CG,36.1%NSAIDs,12.3% CG).4.3% had GC doses&gt;10 mg/day,11.3%&gt; to 20mg/day. The treatment :DMARDs of choice in 100% is MTX,44.1% start doses of 10mg/week and 3.9%7.5 mg/week.The route of choice is oral(55.9% vs 44.1%).92.2% associate GC and 31.7% have not withdrawn them after 6 m.57.8% consider the maximum of MTX 25mg/W.87.1% use doses&lt;10 mg/day,with the most used dose being 5 mg/day(35.6%).Follow-up after the start of DMARDs is performed 72.5% between 4-6 weeks and 12.7% is performed by nursing.100% use DAS 28 and 53.5% also CDAI.31.4% perform PROs (HAQ 83.3%,RAPID 3 14.3%).The use of systematic ultrasound is collected in 33%, being himself who performs it in 59.9% and an expert rheumatologist in 46.1%.Finally, when asked about incidence of pandemic in the follow-up,53.3% consider that it is doing the same as before. 46.1% consider that telephone visits are not suitable for the follow-up of the ERAvs14.7% who consider that Yes.When questioning the situations in which they consider them to be appropriate,75.9% that it was adequate in the control after the beginning of the DMARDs.Regarding the treatment of ERA, 66% delayed the onset of biological DMARDs, 72.1% due to difficulty of follow-up and only 8.8% due to an increased risk of infection. When performing the univariate analysis , it is evident that having a monographic dispensary is associated with earlier onset of MTX(p&lt; 0.001)and at doses≥15 mg/W(p = 0.05),greater nursing intervention(p&lt; 0.001),greater use of PROs(p = 0.008)and there is a tendency to a shorter waiting time for first visits(p = 0.07).It is also associated with not considering telephone visits(p&lt; 0.001), making them in less than 25%(p&lt; 0.0001).Similarly,hospital level is directly proportional to initiation at higher doses of MTX(p&lt; 0.0001),lower use of GC&lt;10mg.Among the rest of the variables, no association has been found. Conclusion The recommendations of EULAR/ACR in the treatment and follow-up of ERA are consistently followed,although the wide use of MTX orally is striking.It is evident that the variable that most influences the early onset of FAME and at higher doses,is a monographic dispensary,as well as greater presence of nursing and performance of PROs. Acknowledgements Thanks to all the members of the Catalan society of reuamtology who participated in the survey Disclosure of Interests None declared